Parkman Healthcare Partners LLC Grows Stock Holdings in Insmed, Inc. $INSM

Key Points

• Parkman Healthcare Partners LLC increased its stake in Insmed, Inc. by 6.3%, holding 37,901 shares valued at approximately $2.89 million after acquiring an additional 2,233 shares in the 1st quarter.
• Insmed's stock has shown a 1.8% increase, with shares recently priced at $145.10, and the company reported a negative EPS of ($1.70) for the most recent quarter, missing forecasts.
• Wall Street analysts are optimistic about Insmed's future, with several raising their price targets; UBS Group set a new target of $133.00, while Morgan Stanley adjusted theirs to $144.00.

Parkman Healthcare Partners LLC raised its holdings in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 6.3% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 37,901 shares of the biopharmaceutical company's stock after acquiring an additional 2,233 shares during the quarter. Parkman Healthcare Partners LLC's holdings in Insmed were worth $2,891,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in the business. M&T Bank Corp boosted its position in shares of Insmed by 4.7% during the 1st quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock worth $252,000 after acquiring an additional 147 shares in the last quarter. Snowden Capital Advisors LLC boosted its position in shares of Insmed by 2.5% during the 4th quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock worth $456,000 after acquiring an additional 158 shares in the last quarter. Cullen Frost Bankers Inc. lifted its position in shares of Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 221 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Insmed by 6.5% during the 1st quarter. Nisa Investment Advisors LLC now owns 3,761 shares of the biopharmaceutical company's stock worth $287,000 after buying an additional 228 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its position in shares of Insmed by 10.5% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 3,231 shares of the biopharmaceutical company's stock worth $223,000 after buying an additional 307 shares during the last quarter.

Insmed Stock Performance

INSM traded up $0.52 on Tuesday, hitting $147.20. 1,461,166 shares of the company traded hands, compared to its average volume of 2,792,917. The company has a 50 day moving average of $116.55 and a 200-day moving average of $90.60. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $31.12 billion, a PE ratio of -25.78 and a beta of 0.97. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $149.08.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The firm had revenue of $107.42 million for the quarter, compared to analysts' expectations of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm's quarterly revenue was up 18.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insider Activity at Insmed

In other news, CFO Sara Bonstein sold 58,400 shares of the business's stock in a transaction that occurred on Monday, July 21st. The stock was sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the sale, the chief financial officer owned 73,505 shares of the company's stock, valued at $7,546,758.35. The trade was a 44.27% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 99,172 shares of Insmed stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total value of $9,264,648.24. Following the transaction, the insider owned 89,407 shares of the company's stock, valued at $8,352,401.94. This represents a 52.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 477,554 shares of company stock worth $49,433,687 in the last three months. 3.00% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on INSM. Royal Bank Of Canada boosted their price objective on shares of Insmed from $108.00 to $120.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. UBS Group boosted their price objective on shares of Insmed from $124.00 to $133.00 and gave the stock a "buy" rating in a research report on Friday, August 8th. Truist Financial upped their target price on Insmed from $126.00 to $139.00 and gave the company a "buy" rating in a research report on Thursday, August 14th. Morgan Stanley upped their target price on Insmed from $126.00 to $144.00 and gave the company an "equal weight" rating in a research report on Thursday, August 21st. Finally, Guggenheim upped their target price on Insmed from $125.00 to $172.00 and gave the company a "buy" rating in a research report on Monday. Sixteen analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Insmed currently has an average rating of "Moderate Buy" and an average price target of $139.86.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.